Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
Ann Pharmacother. 2024 Dec;58(12):1218-1228. doi: 10.1177/10600280241241049. Epub 2024 Apr 2.
This review evaluates the efficacy and safety of novel respiratory syncytial virus (RSV) vaccines approved for adults aged 60 years and older.
A literature search through February 27, 2024 was conducted using search terms, such as RSV, viral respiratory illness, vaccine, RSVpreF, RSVpreF3, Prefusion F, Abrysvo, and Arexvy.
Data from primary literature and vaccine prescribing information were reviewed, encompassing evaluations of clinical pharmacology, efficacy, safety, adverse events, warnings, and precautions.
The literature review process resulted in 10 articles included within this article's scope, including the results of 2 major phase III trials presented in detail. Two RSV vaccines, Respiratory Syncytial Virus Vaccine (recombinant [adjuvanted]; RSVpreF3-ASO1E, Arexvy) and Respiratory Syncytial Virus Vaccine (recombinant; RSVpreF, Abrysvo), approved for preventing RSV-associated lower respiratory tract disease (LRTD) in adults aged 60 years or older in the United States are discussed. Results from Phase III trials have demonstrated the efficacy of 1 dose of these vaccines in preventing RSV-associated LRTD across 2 RSV seasons.
The Advisory Committee on Immunization Practices currently recommends use of these vaccines under shared clinical decision-making for adults aged 60 years or older. Most common adverse effects include injection site reactions (eg, site pain, redness, and swelling). Administration requires a single intramuscular injection of 0.5 mL, reconstituted prior to administration.
The RSVpreF3-ASO1E and RSVpreF vaccines effectively prevent RSV-associated LRTD in adults aged 60 years and older.
本综述评估了已批准用于 60 岁及以上成年人的新型呼吸道合胞病毒（RSV）疫苗的疗效和安全性。
通过使用搜索词（如 RSV、病毒性呼吸道疾病、疫苗、RSVpreF、RSVpreF3、融合前 F、Abrysvo 和 Arexvy），进行了截至 2024 年 2 月 27 日的文献检索。
对主要文献和疫苗说明书中的数据进行了审查，涵盖了临床药理学、疗效、安全性、不良事件、警告和注意事项的评估。
文献综述过程共纳入了 10 篇文章，详细介绍了 2 项主要的 III 期试验结果。讨论了在美国批准用于预防 60 岁及以上成年人 RSV 相关下呼吸道疾病（LRTD）的两种 RSV 疫苗，即呼吸道合胞病毒疫苗（重组[佐剂]；RSVpreF3-ASO1E，Arexvy）和呼吸道合胞病毒疫苗（重组；RSVpreF，Abrysvo）。III 期试验结果表明，这两种疫苗在两个 RSV 季节中均能有效预防 1 剂 RSV 相关 LRTD。
免疫实践咨询委员会目前建议在 60 岁或以上的成年人中根据共同的临床决策使用这些疫苗。最常见的不良反应包括注射部位反应（如注射部位疼痛、发红和肿胀）。给药需要在给药前将 0.5 毫升的 0.5 毫升单剂量肌内注射。
RSVpreF3-ASO1E 和 RSVpreF 疫苗可有效预防 60 岁及以上成年人的 RSV 相关 LRTD。
